These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. FimH antagonists for the oral treatment of urinary tract infections: from design and synthesis to in vitro and in vivo evaluation. Klein T, Abgottspon D, Wittwer M, Rabbani S, Herold J, Jiang X, Kleeb S, Lüthi C, Scharenberg M, Bezençon J, Gubler E, Pang L, Smiesko M, Cutting B, Schwardt O, Ernst B. J Med Chem; 2010 Dec 23; 53(24):8627-41. PubMed ID: 21105658 [Abstract] [Full Text] [Related]
5. Rational design strategies for FimH antagonists: new drugs on the horizon for urinary tract infection and Crohn's disease. Mydock-McGrane LK, Hannan TJ, Janetka JW. Expert Opin Drug Discov; 2017 Jul 23; 12(7):711-731. PubMed ID: 28506090 [Abstract] [Full Text] [Related]
6. Design, synthesis and biological evaluation of mannosyl triazoles as FimH antagonists. Schwardt O, Rabbani S, Hartmann M, Abgottspon D, Wittwer M, Kleeb S, Zalewski A, Smieško M, Cutting B, Ernst B. Bioorg Med Chem; 2011 Nov 01; 19(21):6454-73. PubMed ID: 21962988 [Abstract] [Full Text] [Related]
8. Selective depletion of uropathogenic E. coli from the gut by a FimH antagonist. Spaulding CN, Klein RD, Ruer S, Kau AL, Schreiber HL, Cusumano ZT, Dodson KW, Pinkner JS, Fremont DH, Janetka JW, Remaut H, Gordon JI, Hultgren SJ. Nature; 2017 Jun 22; 546(7659):528-532. PubMed ID: 28614296 [Abstract] [Full Text] [Related]
12. A flow cytometry-based assay for screening FimH antagonists. Scharenberg M, Abgottspon D, Cicek E, Jiang X, Schwardt O, Rabbani S, Ernst B. Assay Drug Dev Technol; 2011 Oct 22; 9(5):455-64. PubMed ID: 21675870 [Abstract] [Full Text] [Related]
15. Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesin. Bouckaert J, Berglund J, Schembri M, De Genst E, Cools L, Wuhrer M, Hung CS, Pinkner J, Slättegård R, Zavialov A, Choudhury D, Langermann S, Hultgren SJ, Wyns L, Klemm P, Oscarson S, Knight SD, De Greve H. Mol Microbiol; 2005 Jan 22; 55(2):441-55. PubMed ID: 15659162 [Abstract] [Full Text] [Related]
16. Glycosylation changes as important factors for the susceptibility to urinary tract infection. Taganna J, de Boer AR, Wuhrer M, Bouckaert J. Biochem Soc Trans; 2011 Jan 22; 39(1):349-54. PubMed ID: 21265802 [Abstract] [Full Text] [Related]
17. Systemic immunization with conserved pilus-associated adhesins protects against mucosal infections. Palaszynski S, Pinkner J, Leath S, Barren P, Auguste CG, Burlein J, Hultgren S, Langermann S. Dev Biol Stand; 1998 Jan 22; 92():117-22. PubMed ID: 9554264 [Abstract] [Full Text] [Related]
18. Antiadhesive natural products against uropathogenic E. coli: What can we learn from cranberry extract? Scharf B, Schmidt TJ, Rabbani S, Stork C, Dobrindt U, Sendker J, Ernst B, Hensel A. J Ethnopharmacol; 2020 Jul 15; 257():112889. PubMed ID: 32311481 [Abstract] [Full Text] [Related]